Calliditas Therapeutics Suisse SA
2 clinical trials · Sponsor
◉ Watch Calliditas Therapeutics Suisse SA
| Record | Firm | Date |
|---|---|---|
| A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) (NCT05323656) | Calliditas Therapeutics Suisse SA | 2022-04-06 |
| A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (NCT05014672) | Calliditas Therapeutics Suisse SA | 2022-02-14 |
Track Calliditas Therapeutics Suisse SA automatically
Every clearance here is in the API, with alerts when new ones post.